NCT07173322

Brief Summary

As there is limited knowledge regarding the impact of CAR-T Cell therapy on fertility, LLS has designed a Patient Survey to learn more about the impact on fertility in patients who have received/are receiving CAR-T Cell treatment. The insights gained from this survey will inform future treatment protocols and fertility preservation strategies.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 9, 2025

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 29, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

September 15, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 9, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 9, 2026

Completed
Last Updated

September 15, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

August 29, 2025

Last Update Submit

September 7, 2025

Conditions

Cancer

Keywords

CancerCAR Tcell treatment

Outcome Measures

Primary Outcomes (1)

  • The Impact of CAR-T Cell Therapy on Fertility

    As there is limited knowledge regarding the impact of CAR-T Cell therapy on fertility, LLS, in collaboration with John Ligon MD and Citizen Health, has designed a Patient Survey to learn more about the impact on fertility in patients who have received/are receiving CAR-T Cell treatment. The insights gained from this survey will inform future treatment protocols and fertility preservation strategies.

    data will be collected for 1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* any cancer patient * at least 18 years of age * with a history of receiving CAR-T Cell treatment.

* any cancer patient * at least 18 years of age * with a history of receiving CAR-T Cell treatment. less than 18 years old. \-

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Internet

Rye, New York, 10573, United States

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Nina Logan, MD

    The Leukemia and Lymphoma Society

    PRINCIPAL INVESTIGATOR

  • John J Ligon, MD

    Univ of Florida, Gainesville

    STUDY CHAIR

Central Study Contacts

Janaela Scott

CONTACT

844-696-7228 (24 hours)Janaela.Scott@lls.org

Brian Chadwick, RN MS

CONTACT

9144145788chadwickbj@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 29, 2025

First Posted

September 15, 2025

Study Start

February 9, 2025

Primary Completion

February 9, 2026

Study Completion

February 9, 2026

Last Updated

September 15, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations

US(1)